Key result
Novel glucose-lowering agents show profound cardiorenal benefits, shifting care toward an integrated cardiometabolic framework.
The past decade of cardiovascular outcome trials has transformed cardiometabolic medicine by demonstrating the cardiorenal protective effects of novel glucose-lowering agents.
The decade from 2016 to 2026 has witnessed an extraordinary transformation in cardiometabolic medicine, propelled by the maturation of cardiovascular outcome trials (CVOTs). What began as regulatory requirements to establish cardiovascular safety for novel glucose-lowering agents has evolved into a robust body of evidence demonstrating profound cardiorenal protective effects-often extending beyond diabetes itself. Landmark trials such as EMPA-REG OUTCOME, LEADER, SELECT, SURPASS-CVOT, and VESALIUS-CV have not only redefined therapeutic priorities but have also catalyzed a conceptual shift from glucocentric management to an integrated cardiorenal metabolic (CRM) framework. This narrative review traces the epidemiological imperatives driving this evolution, chronicles the historical trajectory of CVOTs, synthesizes key findings across major pharmacological classes, and reflects on emerging therapies and risk markers that are shaping the precision-medicine paradigm of 2026.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2026) conducted a review in Cardiometabolic disease. Novel glucose-lowering agents was evaluated. Cardiovascular outcome trials for novel glucose-lowering agents demonstrated profound cardiorenal protective effects, catalyzing a shift to an integrated cardiorenal metabolic framework.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: